Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Mar
11
2022
FDA Publishes Proposed Rule on National Standards for The Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers as Required by The Drug Supply Chain Security Act
Feb
23
2023
THC-Oh No! The DEA Classifies Delta-8 and Delta-9 THCO as Controlled Substances
Dec
29
2015
Don't Blame Patents For High Drug Prices
Mar
29
2020
Whistleblower Suit Against Pharmaceutical Company Heads to Trial
Apr
3
2020
COVID-19: Notable Impacts for Post-Acute Providers from the CARES Act, CMS Blanket Waivers, and the CMS Interim Final Rule
May
14
2013
Environmental Protection Agency (EPA) Establishes June 30 Deadline for Oil and Natural Gas Companies’ Submittal of Requests for Alternative Greenhouse Gas Monitoring Methods
Feb
14
2022
Top Trends in Tech-Enabled Home Care
Jan
7
2019
“Pathways to Success:” CMS Publishes Final Rule Modifying the Medicare Shared Savings Program
Feb
11
2015
House To Consider Keystone, Tax Extenders; Senate To Vote On Director Of National Drug Control Policy
Feb
10
2016
PTAB Institutes Trial On Previously Challenged Cabilly Patent
Nov
23
2020
A Record-Breaking Year in Digital Health Investments: Key Takeaways | HTLH GoLive Webinar
Apr
5
2023
D’Addario v. Johnson & Johnson – New Jersey Federal Court Addresses Express Pre-Emption In Class III Medical Device Case Sills Cummis & Gross P.C.
Jul
9
2011
The NJ Solar Energy Industry: Boom, Correction And The Future - Part I Sills Cummis & Gross P.C.
Mar
17
2014
Letters Of Intent For On-Site Solar Energy Transactions Sills Cummis & Gross P.C.
Sep
18
2016
In Re Reglan Litigation: New Jersey Supreme Court Holds that Failure to Timely Update Claims against Generic Drug Manufacturers Are Not Pre-Empted by Federal Law Sills Cummis & Gross P.C.
Jun
3
2012
Five Traps for the Unwary Licensee Sills Cummis & Gross P.C.
Jun
7
2014
Dietary Supplement Health and Education Act (DSHEA) – 20 Years Later – The Good, The Bad And The Ugly Sills Cummis & Gross P.C.
Feb
26
2021
New Jersey Adult-Use Recreational Cannabis Laws Provide Business Opportunities Sills Cummis & Gross P.C.
Apr
21
2021
New Jersey Appellate Division Finds that Evidence of 510(k) Clearance Cannot be Categorically Excluded in Medical Device Product Liability Cases Sills Cummis & Gross P.C.
Nov
30
2018
In re Accutane Litigation: A Victory for Pharmaceutical Companies on Choice of Law and Label Warnings Sills Cummis & Gross P.C.
Jul
9
2019
Merck Sharp & Dohme Corp. v. Albrecht: The U.S. Supreme Court Weighs In On Preemption Sills Cummis & Gross P.C.
Aug
8
2014
Medical Devices: Parallel Claims Against Device Manufacturers post-Riegel? Sills Cummis & Gross P.C.
Jul
25
2019
Weeding through the NJ Medical Marijuana Law Amendments: What You Need to Know Sills Cummis & Gross P.C.
May
2
2020
Re-Imagining the Shopping Center Post-COVID: Zoning Changes Needed to Accommodate Store Features No Longer Deemed Convenience Amenities Sills Cummis & Gross P.C.
Mar
4
2020
Federal Preemption in the Wake of Albrecht: The U.S. Supreme Court Unexpectedly Levels the Playing Field Sills Cummis & Gross P.C.
Feb
25
2021
New Jersey Cannabis Legalization Imposes New Burdens on Employers Sills Cummis & Gross P.C.
Feb
19
2015
Life Sciences: Protecting the Crown Jewels Sills Cummis & Gross P.C.
Oct
10
2011
Six Important Strategies To Reduce The Royalty Burden For A Pharmaceutical Product Sills Cummis & Gross P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins